These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 23460535)

  • 1. Agonist antibodies to TNFR molecules that costimulate T and NK cells.
    Melero I; Hirschhorn-Cymerman D; Morales-Kastresana A; Sanmamed MF; Wolchok JD
    Clin Cancer Res; 2013 Mar; 19(5):1044-53. PubMed ID: 23460535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
    Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
    Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.
    Waight JD; Gombos RB; Wilson NS
    Hum Antibodies; 2017; 25(3-4):87-109. PubMed ID: 28085016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.
    Sanmamed MF; Pastor F; Rodriguez A; Perez-Gracia JL; Rodriguez-Ruiz ME; Jure-Kunkel M; Melero I
    Semin Oncol; 2015 Aug; 42(4):640-55. PubMed ID: 26320067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
    Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
    Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
    Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
    J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
    Takeda K; Kojima Y; Uno T; Hayakawa Y; Teng MW; Yoshizawa H; Yagita H; Gejyo F; Okumura K; Smyth MJ
    J Immunol; 2010 May; 184(10):5493-501. PubMed ID: 20400706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
    Gaspar M; Pravin J; Rodrigues L; Uhlenbroich S; Everett KL; Wollerton F; Morrow M; Tuna M; Brewis N
    Cancer Immunol Res; 2020 Jun; 8(6):781-793. PubMed ID: 32273279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of CTLA-4 and GITR for cancer immunotherapy.
    Avogadri F; Yuan J; Yang A; Schaer D; Wolchok JD
    Curr Top Microbiol Immunol; 2011; 344():211-44. PubMed ID: 20563707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.
    Ramirez-Montagut T; Chow A; Hirschhorn-Cymerman D; Terwey TH; Kochman AA; Lu S; Miles RC; Sakaguchi S; Houghton AN; van den Brink MR
    J Immunol; 2006 Jun; 176(11):6434-42. PubMed ID: 16709800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
    Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
    An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
    Dempke WCM; Fenchel K; Uciechowski P; Dale SP
    Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors.
    Zhou P; L'italien L; Hodges D; Schebye XM
    J Immunol; 2007 Dec; 179(11):7365-75. PubMed ID: 18025180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
    Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
    Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.
    Martinez-Forero I; Azpilikueta A; Bolaños-Mateo E; Nistal-Villan E; Palazon A; Teijeira A; Perez-Chacon G; Morales-Kastresana A; Murillo O; Jure-Kunkel M; Zapata JM; Melero I
    J Immunol; 2013 Jun; 190(12):6694-706. PubMed ID: 23690480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
    J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.
    Melero I; Johnston JV; Shufford WW; Mittler RS; Chen L
    Cell Immunol; 1998 Dec; 190(2):167-72. PubMed ID: 9878117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-1BB agonism: adding the accelerator to cancer immunotherapy.
    Chester C; Ambulkar S; Kohrt HE
    Cancer Immunol Immunother; 2016 Oct; 65(10):1243-8. PubMed ID: 27034234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.